Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.

Overview

This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.

Patients initiating erenumab treatment between 20.9.2018 - 15.10. 2019, and data on sick leave days, diagnoses and health care visits as well as medications based on prescriptions were assessed. Following time frames for analyses of sick leaves and health care utilization in patients on erenumab treatment and in controls were reported: Follow-up analyses: For cases (erenumab) with occupational healthcare, a minimum of 12 months on erenumab treatment was required for the analysis of sick leaves and visits Pre erenumab: Follow-up data before index (defined as the first reimbursement decision/prescription for erenumab, or initiation of erenumab injections (before reimbursement approval)) from the Terveystalo database of those with consent Post erenumab: Follow-up data after index, from the Terveystalo database of those with consent Time frames for comparison (sick leaves and visits): One year before index vs. \>12 months erenumab after index, One year before index vs. 6-12 months of erenumab after index (patient years), sensitivity analysis Time frames for comparison (medications): 12 months before index vs. 12 months post follow-up Controls (triptan treated migraine patients): Corresponding time frames as in cases.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes